XTalks

NOVEMBER 9, 2022

Since Mounjaro’s May US Food and Drug Administration (FDA) approval, sales of the drug have skyrocketed beyond initial expectations owing to patient demand and a temporary shortage of Novo’s Ozempic. GIP is a metabolic hormone that promotes insulin secretion and also weakly inhibits gastric acid secretion to suppress appetite.

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5 billion in Q4 2022.

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

NOVEMBER 3, 2022

Mounjaro has thus taken off stronger than expected, surpassing Wall Street sales forecasts during the third quarter. Mounjaro was approved this summer as a Type 2 diabetes treatment and is the first diabetes drug with dual action, targeting two hormones involved in insulin production and appetite (GIP and GLP-1).

Sales 98

Sales FDA Approval Production Insulin 98

XTalks

AUGUST 2, 2023

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. 5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. billion in pharmaceutical sales from 2021.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

JULY 19, 2024

The meteoric rise in the popularity of GLP-1 medications has created a breeding ground for online scams and the sale of unauthorized products,” said LegitScript CEO Scott Roth in a press release.

Pharmacy 104

Pharmacy Drugs Production Sales 104

XTalks

JANUARY 23, 2024

Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This rare endocrine disorder, characterized by inadequate secretion of growth hormone from the pituitary gland, has profound impacts on physical and sometimes cognitive development.

Development 72

Development Hormones Drugs Trials 72

XTalks

MARCH 8, 2021

billion in sales last year, making it the company’s biggest revenue generator in 2020. GLP-1 receptor agonists mimic the action of GLP-1, an intestinal hormone that stimulates the secretion of insulin when blood glucose levels rise. Semaglutide acts by inhibiting glucagon, which is a hormone that increases blood sugar.

Insulin 98

Insulin Hormones Clinical Trials Clinical Trials 98

XTalks

JUNE 20, 2022

TTR is made in the liver and is involved in carrying the thyroid hormone thyroxine (T4) and retinol (vitamin A) to the liver. billion in global sales by 2026. Pfizer has not one but two approved ATTR cardiomyopathy therapies, Vyndaqel and Vyndamax, which secured $2 billion in sales last year.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

pharmaphorum

FEBRUARY 3, 2022

Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. This post looks at dealing with sudden stress and turning it into positive energy. Visualise success. About the author.

Life Science 98

Life Science Hormones Sales Marketing 98

XTalks

MARCH 22, 2021

As a leader in life sciences, diagnostics and applied chemical markets, it is looking to grow its cancer diagnostics pipeline. Resolution has been a leader in the development of NGS-based companion diagnostics (CDx) test development and registration services for precision oncology.

Life Science 110

Life Science Development Marketing Gene Expression 110

The Pharma Data

MARCH 31, 2022

The company’s Supply Center in Berlin will be transformed into a Center of Excellence for parenterals, and the Supply Center in Leverkusen into a Center of Excellence for non-hormonal solids. The Supply Center Bergkamen will become a Center of Excellence for contrast media and hormone products while expanding capacities for therapeutics.

Production 52

Production Manufacturing Hormones Gene Therapy 52

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.

FDA Approval 52

FDA Approval Drugs Sales Development 52

The Pharma Data

MARCH 11, 2021

The company is taking steps aimed at strengthening sales growth, profitability and free cash flow. We plan to continue to grow at Pharmaceuticals despite patent expirations and only expect to register a modest decline in sales in 2024,” he said. Speeding up sales growth. through 2023.

Sales 52

Sales Gene Therapy Marketing Gene 52

XTalks

MARCH 15, 2023

Norepinephrine is a hormone and neurotransmitter that helps in alertness and maintaining control in high-stress situations. In 2022, global sales of the drug totalled $115.3 Since its 2021 approval, Qelbree made a significant leap in sales last year due to its expanded approval in adults, having gone from $9.9 million in 2022.

Drugs 98

Drugs Sales Trials Marketing 98

pharmaphorum

JUNE 7, 2022

Exact Sciences is pioneering diagnostics that enable personalised medicine for cancer patients. Steven joined Exact Sciences in April 2021 as Vice President Medical, International.

Medicine 90

Medicine Life Science Hormones Doctors 90

XTalks

NOVEMBER 20, 2023

AstraZeneca has won its first-in-class approval for its AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for treating patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. billion to $1.28

HR 98

HR FDA Approval Gene Trials 98

XTalks

NOVEMBER 9, 2023

Since its approval in May 2022, Mounjaro sales have hit $1.4 In the first half of 2023, sales of Ozempic and Wegovy rose by 58 percent and 363 percent, respectively. “In Zepbound contains mimetics of the GLP-1 and GIP hormones that regulate appetite and blood sugar. billion in just one year and a quarter. billion for Novo.

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

XTalks

MARCH 25, 2024

They work by mimicking the action of the naturally occurring hormone GLP-1, which is involved in regulating blood sugar and appetite. Access is complex, just like the disease itself is complex,” said Negelle Morris, Novo’s senior VP of cardiometabolic sales. Oprah asked why coverage of weight loss drugs is still limited.

Drugs 105

Drugs Medicine Life Science Production 105

The Pharma Data

FEBRUARY 21, 2022

Elinzanetant, a non-hormonal development compound, is currently being investigated in the Phase III clinical development program OASIS for the treatment of vasomotor symptoms during menopause. Every year 47 million women enter menopause, a period where women are at the peak of their life’s activity, personally and professionally.

Radiology 52

Radiology Cardiology Development Production 52

XTalks

MARCH 8, 2024

According to Amgen’s last earnings report , Prolia sales increased 12 percent last year to more than $4 billion, and Xgeva’s jumped five percent from last year to $2.1 Risk factors include aging, hormonal changes, low body weight, low calcium intake and use of certain medications.

Drugs 59

Drugs FDA Approval Production Immune Response 59

The Pharma Data

APRIL 11, 2023

About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 The company’s approach to research prioritizes targets and pathways with the potential to impact the way that cancer is treated.

Research 40

Research Clinical Trials Clinical Trials Trials 40

XTalks

AUGUST 10, 2022

Approximately 80 to 85 percent of these cases were previously considered to be the HER2-negative subtype (which includes hormone receptor positive and triple negative breast cancer), which means the tumors do not make higher than normal amounts of the HER2 protein.

FDA Approval 98

FDA Approval HR Hormones Antibody 98

Pharmaceutical Technology

APRIL 24, 2023

. “Biologics products may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system.

Contract Manufacturing 130

Contract Manufacturing Manufacturing Protein Sales 130

XTalks

NOVEMBER 26, 2024

The year 2023 was no exception, with several cancer drugs achieving remarkable sales milestones, reflecting their efficacy, expanding indications and the growing global cancer burden. In this blog, we highlight the top 10 cancer drugs to watch in 2024, based on their impressive 2023 sales figures and anticipated market dynamics.

Sales 105

Sales FDA Approval Drugs Marketing 105

XTalks

DECEMBER 6, 2024

While both semaglutide and tirzepatide have a glucagon-like peptide-1 (GLP-1) agonist component, tirzepatide also acts as an agonist of the gastric inhibitory polypeptide (GIP) hormone; this serves as a differentiator between the two and could explain tirzepatides stronger weight loss effects.

Trials 98

Trials Clinical Trials Clinical Trials Marketing 98

XTalks

MAY 20, 2022

Life science industry data analytics company Evaluate Vantage predicts that Mounjaro could bring in $4.9 billion in sales for Lilly by 2026. Trulicity and Jardiance (developed jointly with Boehringer Ingelheim) are Lilly’s other diabetes blockbusters, which totalled sales of more than $10 billion last year.

Insulin 52

Insulin Life Science Drugs Sales 52